Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07119117
ABSTRACT:
The present invention provides non-alpha-tocopherol enriched tocopherol compositions and non-alpha-tocopherol metabolite enriched compositions for use in the reduction of inflammatory markers associated with inflammation such as C-reactive protein.
REFERENCES:
patent: 4325965 (1982-04-01), Chiba
patent: 5139796 (1992-08-01), Barkalow et al.
patent: 5200214 (1993-04-01), Barkalow et al.
patent: 5252604 (1993-10-01), Nagy et al.
patent: 5484816 (1996-01-01), Yanagida et al.
patent: 5804168 (1998-09-01), Murad
patent: 5961993 (1999-10-01), Boussouira et al.
patent: 6024941 (2000-02-01), Yanagida et al.
patent: 6024960 (2000-02-01), Kharazmi et al.
patent: 6048891 (2000-04-01), Wechter
patent: 6239171 (2001-05-01), Lane et al.
patent: 6242479 (2001-06-01), Wechter
patent: 6346544 (2002-02-01), Hensley
patent: 6410589 (2002-06-01), Wechter
patent: 6716451 (2004-04-01), Udell et al.
patent: 6780886 (2004-08-01), Kondo et al.
patent: 2002/0006954 (2002-01-01), Hensley et al.
patent: 2002/0040053 (2002-04-01), Kondo et al.
patent: 2002/0143049 (2002-10-01), Miller et al.
patent: 2004/0082649 (2004-04-01), Rich et al.
patent: 2004/0106674 (2004-06-01), Rich et al.
patent: 2004/0116512 (2004-06-01), Naguib et al.
patent: WO 96/19214 (1996-06-01), None
patent: WO 00/44375 (2000-08-01), None
patent: WO 00/57876 (2000-10-01), None
patent: WO 01/02004 (2001-01-01), None
Yuan et al., Zhongiao Bingli Shengli Zazhi (1994) 10(6), 649-53 (abstract).
Jiang et al., Proceedings of the National Academy of Sciences (Oct. 10, 2000) 97/21 (11494-11499) (abstract).
“Optimal Ratio Mixed Vitamin E Complex for Advanced Antioxidant Protection”,Metagenics Through Nutrition, Formula Focus,MET181, 7-01 (2 pgs.), 2001.
Upritchard, et al., “Effect of Supplementation with Tomato Juice, Vitamin E, and Vitamin C an LDL Oxidation and Products of Inflammatory Activity in Type 2 Diabetes”,Diabetes Care, 23:733-738, 2000.
Akpolat et al. (2000). “Effect of vitamin E and Pentoifylline on glycerol-induced acute renal failure.”Nephron84:243-247.
Appenroth et al. (2001). “LLU-α, and endogenous metabolite of γ-tocopherol, is more effective against metal nephrotoxicity in rats than γ-tocopherol.”0Toxicology Letters122:255-265.
Bieri & Evarts. (1973). “Vitamin E activity of γ-tocopherol in the rat, chick and hamster.”J. Nutr.104:850-857.
Boaz et al. (2000). Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.The Lancet356:1213-1218.
Chapkin et al. (1983). “Effect of vitamin E supplementation on serum and high-density lipoprotein cholesterol in renal patients on maintenance hemodialysis.”Am.J. Clin. Nutr.38:253-256.
Dillard et al. (1983). “Relative antioxidant effectiveness of α-tocopherol and γ-tocopherol in iron-loaded rats”.J. Nutr.113:226-2273.
Fryer, Michael J. (1999). “Treatment of acute renal failure with antioxidant vitamin E.”Renal Failure21(2) 231-233.
Jiang et al. (2000). “γ-tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells.”PNAS97(21):11494-11499.
Jiang et al. (2001). “γ-tocopherol, the major form of vitamin E in the US diet, deserves more attention.”Am. J. Clin. Nutr.74:714-722.
Kim, et al. (2000). “Vitamin E and Probucol reduce urinary lipophilic aldehydes and renal enlargement in Streptozotocin-induced diabetic rats.”Lipids35(11):1225-1236.
Patrick, L and Uzick, M. (2001) “Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.”0Alternative Medicine Review6(3):248-271.
Raloff, Janet. (2001). “Vitamin E targets dangerous inflammation”.Science Newsvol. 159, No. 15.
Sharma et al. (1999). “Lipid peroxide levels in chronic renal failure.”0JAPI47(3):296-297.
Tepel, et al. (2002). “Antioxidative Therapie bei Gefaβ—und Nierenerkrankungen”.Medizinische Klinik97:144-151.
Upritchard et al. (2000). “Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes.”Diabetes Care53:733-738.
Vessby et al. (2002). “Oxidative stress and antioxidant status in type 1 diabetes mellitus.”J. Internal Med.251:69-76.
Wijnen et al. (2002). “Can renal dysfunction after infra-renal aortic aneurysm repair be modified by multi-antioxidant supplementation?”J. Cardiovasc. Surg.43:483-488.
Yuan, et al. (1994). “The change of intracellular free calcium ion concentration and interleukin-1 activity of mononuclear cells in chronic renal failure rats”. Chinese Journal of Pathophysiology, 10(6):649-653.
Beinlich Peggy
Boddupalli Sekhar
Brown Lesley A.
Dreon Darlene M.
Flaim Stephen
Foley & Lardner LLP
Galileo Pharmaceuticals, Inc.
Spivack Phyllis G.
LandOfFree
Tocopherol enriched compositions and amelioration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tocopherol enriched compositions and amelioration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tocopherol enriched compositions and amelioration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3648554